ANVISA-2020-0085-V085

Type II variation for application ANVISA-2020-0085. Type II variation: Analytical Method Change for Tisagenlecleux-B — critical change

Variation Number
ANVISA-2020-0085-V085
Type
Type II
Application
ANVISA-2020-0085
Change
CHG-2024-0085
Status
Draft
Fee
€48,507
Submitted
2024-02-05
Approved
—
Description

Type II variation: Analytical Method Change for Tisagenlecleux-B — critical change